Home   >   News & Events   >   News   >   Data from Inovalon’s MORE2 Registry® Enables Pharmacovigilance Research
June 12, 2014

Data from Inovalon’s MORE2 Registry® Enables Pharmacovigilance Research

Research Accepted as Podium Presentation at the American Diabetes Association 74th Scientific Sessions

BOWIE, Md. – June 12, 2014 – Inovalon, Inc., a leading technology company providing advanced cloud-based analytics and data-driven solutions to the healthcare industry, today announced a comparative safety research study to be presented at the American Diabetes Association 74th Scientific Sessions June 13-17 in San Francisco, California. The study was supported by data from Inovalon’s Medical Outcomes Research for Effectiveness and Economics Registry (MORERegistry®).

Inovalon’s Statistical Research Team will be present “Comparative Safety of Oral Antidiabetic Therapy on Risk of Fracture in Patients with Diabetes.” The purpose of this study was to address the lack of evidence of relative advantage of one antidiabetic drug class over the other with respect to risk of fracture as outlined in the Agency for Healthcare Research and Quality (AHRQ) 2011 comparative effectiveness review on oral medications for Type 2 Diabetes. To our knowledge, this study is the first report to include a drug class-level comparison of risk of fracture related to all antidiabetic drug classes using a large administrative claims database. Information about the relative advantage of one drug over the other can be useful to support optimal treatment decisions and can have major implications for reducing healthcare costs.

“A key advantage of large retrospective data such as our MORE2 Registry is the ability to conduct large observational studies not possible with data reported by typically small clinical trials,” said Dan Rizzo, Chief Innovation Officer at Inovalon. “The goal is to help answer the question: ‘What works best under what conditions for what patients?’ This research will support development of evidence based guidelines and practices better tailored to individual patient characteristics to support optimal treatment plans.”

Inovalon’s Health Services Researchers, co-authors of the research include: Sandhya Mehta, PhD; Barton T. Jones, MS; Antoine Kfuri, MD, MPH, CMQ; and Christie Teigland, PhD.

The presentations will be held on Sunday, June 15 at 8:00 a.m.

About Inovalon, Inc.

Inovalon is a leading technology company that combines advanced cloud-based data analytics with highly targeted interventions to achieve meaningful impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Inovalon’s unique achievement of value is delivered through the effective progression of Turning Data into Insight, and Insight into Action®. Large proprietary datasets, advanced integration technologies, sophisticated predictive analytics, and deep subject matter expertise deliver a seamless, end-to-end platform of technology and nationwide operations that bring the benefits of big data and large-scale analytics to the point of care. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while also bringing to bear the unique capabilities to resolve them. Touching more than 540,000 physicians, 220,000 clinical facilities, and more than 140 million Americans, this differentiating combination provides a powerful solution suite that drives high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, patients, and researchers. For more information visit


Inovalon, Inc.
Kim E. Collins
4321 Collington Road
Bowie, Maryland 20716
Phone: 301-809-4000 x1473

Greenough Communications,
on behalf of Inovalon, Inc.
Andrea LePain
Phone: 617-275-6526

© 2019 Inovalon. All rights reserved.